Fecal microbiota transplant from healthy donors may lower primary resistance to immunotherapy with anti-PD-1 agents among patients with advanced or metastatic melanoma, results of the phase 1 MIMic trial showed.
2022
Sequencing of surgery, immunotherapy impacts outcomes in melanoma
The sequence of surgery and immunotherapy affects outcomes for patients with melanoma, according to a speaker at Chemotherapy Foundation Symposium.
Melanoma cases higher in rural areas, study finds
LANSING – Residents of Michigan’s rural counties are much more likely to get melanoma – skin cancer – than urban residents in the state, a new study has found.
Potential Impact of Tumor Infiltrating Lymphocytes on Melanoma Treatment
Ryan Sullivan, MD, associate professor, Medicine, Harvard Medical School and associate professor, Hematology/Oncology, Massachusetts General Hospital, explains how tumor infiltrating lymphocytes (TIL) could impact the melanoma treatment landscape if approved by the FDA.